GoAI
Get started
Genprex, Inc. logo

Genprex, Inc.

GNPX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.95

$0.00 · 0.00%

Aug 21, 4:00 PM ET

GNPX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

48

Fair Value

Momentum

16

Strong Down

Sentiment

44

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Ryan Confer
Listed since
Mar 29, 2018
Employees
13

Market position

Day range

Current $3.95

52-week range

Current $3.95

Open
$3.90
Previous close
$3.95
Volume
96.48K
0.75× average
Average volume
129.45K
Average daily volume
Market cap
1.99M USD
Beta
-0.89
Market reference 1
50-day average
$8.5188
-53.63% below average
200-day average
$35.6093
-88.91% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.02×
P/B (TTM)
0.13×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×

Financial statements

Income trends

Operating income

−15.52M USD+26.72%

Net income

−16.23M USD+23.13%
Income trends across reported periods−13.96M USD−20.18M USD−26.41M USD−32.63M USDOperating income, FY2021: −20.67M USDOperating income, FY2022: −23.83M USDOperating income, FY2023: −31.08M USDOperating income, FY2024: −21.17M USDOperating income, FY2025: −15.52M USDNet income, FY2021: −20.66M USDNet income, FY2022: −23.74M USDNet income, FY2023: −30.86M USDNet income, FY2024: −21.11M USDNet income, FY2025: −16.23M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −20.67M USD. Operating income FY2022 −23.83M USD. Operating income FY2023 −31.08M USD. Operating income FY2024 −21.17M USD. Operating income FY2025 −15.52M USD. Net income FY2021 −20.66M USD. Net income FY2022 −23.74M USD. Net income FY2023 −30.86M USD. Net income FY2024 −21.11M USD. Net income FY2025 −16.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—6.69K USD15K USD25.58K USD22.53K USD
Gross profit—−6.69K USD−15K USD−25.58K USD−22.53K USD
Research and development9.43M USD10.54M USD17.62M USD11.51M USD8.97M USD
Selling, general, and administrative6.09M USD10.63M USD13.44M USD12.3M USD11.68M USD
Operating expenses15.52M USD21.17M USD31.06M USD23.81M USD20.65M USD
Interest income—63.57K USD215.11K USD90.1K USD5.13K USD
Interest expense739.94K USD————
Depreciation and amortization—6.69K USD15K USD25.58K USD22.53K USD
Operating income−15.52M USD−21.17M USD−31.08M USD−23.83M USD−20.67M USD
Net income−16.23M USD−21.11M USD−30.86M USD−23.74M USD−20.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
22%
2 beats, 7 misses, 0 met estimates
Average EPS surprise
-1934.82%
9 comparable reports
Latest EPS result
-9.4

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-7.99-491.67-975.35-1,459.03Q4 '24MissQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 13, 2024: actual -1,351.65, estimate -1,241.76, surprise -8.85%, Miss. Q2 2025, reported Apr 1, 2025: actual -462, estimate -18.04, surprise -2460.98%, Miss. Q2 2025, reported May 12, 2025: actual -285.71, estimate -55.88, surprise -411.29%, Miss. Q3 2025, reported Aug 8, 2025: actual -187, estimate -15.62, surprise -1097.18%, Miss. Q4 2025, reported Nov 14, 2025: actual -109.89, estimate -275, surprise +60.04%, Beat. Q1 2026, reported Mar 30, 2026: actual -25.3, estimate -286, surprise +91.15%, Beat. Q2 2026, reported May 13, 2026: actual -14.07, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -9.4, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

GNPX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GNPX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.9K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research GNPX

research.disclaimer